A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TTFields / Tumor Treating Fields

[Related PubMed/MEDLINE]
Total Number of Papers: 119
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TTFields  (>> Co-occurring Abbreviation)
Long Form:   Tumor Treating Fields
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Theoretical Analysis of the Effects of Tumor-Treating Electric Fields on Single Cells. ---
2020 A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis. DEP
2020 An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications. GBM, MPM
2020 Barium Titanate Nanoparticles Sensitise Treatment-Resistant Breast Cancer Cells to the Antitumor Action of Tumour-Treating Fields. BTNPs
2020 Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. CBCT, CTV, IMRT, IST/IIT, PCA
2020 Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields. CR, GBM, OS, PFS, STR, TMZ
2020 Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study. AEs, ndGBM, OS, PFS, RT, TMZ
2020 Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. GTV
2020 Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. ---
10  2020 Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. AE, GBM, US, EMEA
11  2020 Heat transfer during TTFields treatment: Influence of the uncertainty of the electric and thermal parameters on the predicted temperature distribution. EF
12  2020 Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. AEs
13  2020 The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. NGS
14  2020 The Value of Tumor Treating Fields in Glioblastoma. FDA, GBM
15  2020 Thermoplastic microfluidic bioreactors with integrated electrodes to study tumor treating fields on yeast cells. ---
16  2020 Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics. GEF-H1, RhoA, ROCK
17  2020 Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. DSBs
18  2020 Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies. GBM
19  2020 Tumor Treating Fields in the Management of Patients with Malignant Gliomas. GBM, MOA, ndGBM, rGBM, TMZ
20  2020 Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. GBM, PFS
21  2020 Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. DCs
22  2020 Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. CTCAE, MGMT, ndGBM, OS, PFS
23  2019 5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy. 5-FU, CRC
24  2019 Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells. ---
25  2019 Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial. HR, LMiDD, OS, PFS
26  2019 Efficacy of 150kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro. ---
27  2019 Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions. CAR, CFSE, MOA, PB, TILs
28  2019 Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models. ---
29  2019 Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. OS, PFS
30  2019 Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies. ---
31  2019 Optimization of tumor treating fields using singular value decomposition and minimization of field anisotropy. FA, FE, GBM
32  2019 Patient Reported Outcome (PRO) Among High-Grade Glioma Patients Receiving TTFields Treatment: A Two Center Observational Study. DSQ, HGG, PRO
33  2019 The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma. ---
34  2019 The combined treatment of 150kHz Tumor Treating Fields (TTFields) and sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma. ---
35  2019 The dielectric properties of skin and their influence on the delivery of tumor treating fields to the torso: a study combining in vivo measurements with numerical simulations. SAT
36  2019 Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. BEV, GBM, IRI, OS, PFS, rGBM, TMZ
37  2019 Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. CR, GBM, ICER, OS, PFS, QALYs, TMZ
38  2019 Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune System. GBM, TMZ
39  2019 Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. AEs, OS, PDAC, PFS, SAEs
40  2019 Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. ---
41  2019 Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. SAR
42  2019 What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? GBM, TMZ
43  2019 [Tumor treating fields in cancer treatment in Denmark]. ---
44  2019 [Tumor treating fields in cancer treatment in Denmark]. ---
45  2018 A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling. ---
46  2018 Acceptance and compliance of TTFields treatment among high grade glioma patients. GBM, rHGG
47  2018 Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma. AMT
48  2018 AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). AMPK, ATG7, CQ, ER, LC3-II
49  2018 Direct-Current Electric Field Distribution in the Brain for Tumor Treating Field Applications: A Simulation Study. ---
50  2018 Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ddTMZ, PFS
51  2018 Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy. VMAT
52  2018 Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study. GBM, OAR, RT, TTField
53  2018 Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. EOT, GBM, SAC
54  2018 Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. TMZ
55  2018 Estimating the Intensity and Anisotropy of Tumor Treating Fields Jsing Singular Value Decomposition. Towards a More Comprehensive Estimation of Anti-tumor Efficacy. FE
56  2018 Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. ROS
57  2018 Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations. ---
58  2018 Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. HRQoL
59  2018 The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists. GBM, OS
60  2018 Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. ---
61  2018 Tumor treating fields increases membrane permeability in glioblastoma cells. ---
62  2018 Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors. ---
63  2018 Tumor Treating Fields: Adjuvant Treatment for High-grade Gliomas. ---
64  2018 Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. CI, OR, WMD
65  2018 Tumour treating fields in a combinational therapeutic approach. GBM
66  2018 Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. FET
67  2017 A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. ---
68  2017 Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma. EVH, GTV, SARVH
69  2017 Biological activity of tumor-treating fields in preclinical glioma models. TMZ
70  2017 Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. GBM, OS, PFS, TMZ
71  2017 Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). ---
72  2017 Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. ---
73  2017 End-to-end workflow for finite element analysis of tumor treating fields in glioblastomas. FEA, MRI
74  2017 Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. CFB, GBM, HRQoL, KPS, MMSE, TMZ
75  2017 Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study. ---
76  2017 Skin toxicities associated with tumor treating fields: case based review. ---
77  2017 Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. GBM
78  2017 The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. GBM, GSCs, MGMT, TMZ
79  2017 Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. DSBs, RT
80  2017 Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. DSB, GBM, NSCLC
81  2017 Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. OS
82  2017 Tumor-Treating Fields: Nursing Implications for an Emerging Technology
. ---
83  2016 Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. ---
84  2016 An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. ---
85  2016 An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields. GBM
86  2016 Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. ---
87  2016 Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy. GBM
88  2016 Electrical stimulation towards melanoma therapy via liquid metal printed electronics on skin. ---
89  2016 First steps to creating a platform for high throughput simulation of TTFields. FDA, GBM
90  2016 Glioblastoma: Overview of Disease and Treatment. GBM
91  2016 Improving Tumor Treating Fields Treatment Efficacy in Patients With Glioblastoma Using Personalized Array Layouts. ---
92  2016 Investigating an alternative ring design of transducer arrays for tumor treating fields (TTFields). FDA
93  2016 Optune: Practical Nursing Applications. GBM
94  2016 Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. MRI
95  2016 Rationale and Background on Tumor-Treating Fields for Glioblastoma. GBM
96  2016 Simplified realistic human head model for simulating Tumor Treating Fields (TTFields). GBM
97  2016 Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series. GBM, OS
98  2016 Tumor treating fields: a novel treatment modality and its use in brain tumors. GBM, OS, PFS, TMZ
99  2016 Using computational phantoms to improve delivery of Tumor Treating Fields (TTFields) to patients. ---
100  2015 An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas. ---